Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer

BACKGROUND: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Bone Oncol
Asıl Yazarlar: Hilton, J.F., Clemons, M., Pond, G., Zhao, H., Mazzarello, S., Vandermeer, L., Addison, C.L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709351/
https://ncbi.nlm.nih.gov/pubmed/29204337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2017.11.001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller